Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , April 4, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2023 following the close of market on Tuesday, April 25, 2023.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Illumina to Announce First Quarter 2023 Financial Results on Tuesday, April 25, 2023

Strong demand drives record orders SAN DIEGO , April 4, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has already exceeded more than 200 orders for its revolutionary NovaSeq X sequencing system in the first quarter of 2023. The orders represent a diverse customer base spanning research and clinical customer segments in nearly 30 countries, across five continents, all seeking to add NovaSeq X – our fastest, most powerful, most sustainable high-throughput sequencer available.

Illumina's revolutionary NovaSeq X exceeds 200th order milestone in first quarter 2023

The Federal Trade Commission (FTC) has issued an Opinion and Order requiring DNA sequencing provider, Illumina Inc (NASDAQ:ILMN), to divest Gral Inc, which makes a multi-cancer early detection (MCED) test. In a statement on its website, the FTC said the deal would stifle competition and innovation in the US market for life-saving cancer tests.

FTC orders Illumina to divest cancer detection test maker Grail to protect competition; Illumina to appeal

The FTC ordered Monday that biotech firm Illumina must unwind its $8 billion purchase of the cancer-testing startup Grail. ILMN stock fell on the news.

FTC Orders Biotech Illumina To Unwind Grail Deal Amid Icahn Battle

The Federal Trade Commission on Monday ordered Illumina Inc. ILMN, -1.38% to divest Grail Inc., saying that “the deal would stifle competition and innovation in the U.S. market for life-saving cancer tests.” Illumina said it will appeal the decision in a federal appeals court, thus staying the order until an appeals verdict is reached.

FTC orders Illumina to divest Grail; Illumina plans to appeal

The decision reverses an administrative judge's ruling that dismissed the FTC's initial challenge of Illumina's $7.1 billion Grail deal.

FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail

SAN DIEGO , April 3, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it will appeal the Federal Trade Commission's ("FTC") decision ordering the unwinding of Illumina's acquisition of GRAIL. Illumina intends to file a petition for review promptly with a US Court of Appeals and will seek expedited treatment of the appeal.

Illumina Will Appeal FTC Decision in Federal Court, Will Seek US Resolution by Late 2023 or Early 2024

The agency said the combination would hurt competition for cancer-detection tests while raising prices.

FTC Rejects Illumina's $7 Billion Deal for Cancer-Test Developer Grail

Icahn Enterprises

Activist investor Carl Icahn ramped up his proxy fight against Illumina with a blistering statement.

Carl Icahn blasts Illumina for nearly doubling CEO's pay despite steep drop in market value

ChargePoint Holdings

NXP Semiconductors

Enphase Energy

Mobileye Global Inc

Rivian Automotive

Skyline Corp.

The entire stock market is gearing up for a major breakout as investors are becoming convinced that the banking sector has stabilized and that the Federal Reserve is, at the very least, almost done hiking interest rates. Meanwhile, two critical sectors –housing and computer chips — are showing signs of recovery.

7 Stocks Gearing Up for a Major Breakout

Illumina told shareholders that Carl Icahn's board nominees would "threaten the progress" of the biotech company's core business.

Illumina urges shareholders to reject Carl Icahn's board nominees as proxy fight heats up

SAN DIEGO , March 30, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today filed its preliminary proxy statement with the Securities and Exchange Commission, which contains important information for shareholders. The activist investor Carl Icahn has nominated three of his associates to stand for election to the Board of Directors at Illumina's 2023 Annual Meeting of Shareholders.

Illumina Files Preliminary Proxy, Urging Shareholders to Vote for Its Director Nominees and Withhold for Each Icahn Group Nominee

Illumina's (ILMN) Connected Software is an end-to-end software system that standardizes analysis tools and connects data across the genomics workflow.

Illumina (ILMN) to Enable Tertiary Analysis With New Launch

Icahn said Illumina should bring back former CEO Jay Flatley, saying current management is making the mistake of holding onto the $7.1 billion Grail deal.

Carl Icahn wants to bring back Illumina's ex-CEO 'immediately' as proxy fight intensifies

Illumina Inc. ILMN activist shareholder and billionaire Carl Icahn told The Wall Street Journal he'd like to see the return of ex-CEO Jay Flatley to replace the gene sequencing device maker's current CEO Francis De deSouza. Icahn spoke to the newspaper after launching a proxy campaign earlier in March and nominating three people to the company's board, as disclosed in a letter to shareholders that focused on the company's acquisition of Grail, a cancer screening company.

Carl Icahn tells WSJ he wants old CEO back at Illumina

Microsoft

Twist Bioscience Corp

Western Digital

SAN DIEGO--(BUSINESS WIRE)--The DNA Data Storage Alliance, a SNIA Technology Affiliate, formed in 2020 by Illumina, Inc. (NASDAQ: ILMN), Microsoft (Nasdaq: MSFT), Twist Bioscience Corporation (NASDAQ: TWST) and Western Digital (NASDAQ: WDC) to create and promote an interoperable storage ecosystem based on DNA as a data storage medium, today announced the appointments of CATALOG Technologies and Quantum Corporation to the governing board of the Alliance.

DNA Data Storage Alliance Announces Board Appointments

The billionaire activist, who has launched a proxy battle at Illumina, wants change at the management level too, and he has a candidate in mind for the top spot: former CEO Jay Flatley.

Carl Icahn Wants to Bring Illumina's Old CEO Back

Icahn, who owns a 1.4% stake in Illumina, began his latest proxy battle on March 13, criticizing management for pursuing the 2021 Grail deal amidst regulatory scrutiny.

Illumina Hits Back at Carl Icahn's Grail Deal Claims and His Board Nominations

Illumina is still facing issues around its GRAIL acquisition. The company has seen continued uncertainty and has incurred a lot of losses with the GRAIL acquisition while the core business was performing soft.

Illumina: What Is Up With The Genes?

As demand for clinical next-generation sequencing grows, Illumina Connected Insights enables user to streamline data interpretation and report generation to inform precision care SAN DIEGO , March 27, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of Connected Insights, a new cloud-based software enabling tertiary analysis for clinical next-generation sequencing (NGS) data. Expanding on Illumina's Connected Software portfolio, Connected Insights is designed to streamline interpretation and reporting from a range of assay types, enabling labs to scale use of NGS and reduce turnaround time of clinical reporting via integration of third-party knowledge bases.

Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease

SAN DIEGO , March 24, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, issued the following statement in response to a letter from Carl Icahn dated March 24, 2023: Directors and Officers (D&O) insurance and corporate indemnification are standard for Delaware companies, and support directors in making decisions in the best interests of shareholders. All major U.S. public companies, including Illumina, regularly review their D&O insurance to reflect appropriate coverage.

Illumina Issues Statement in Response to Carl Icahn's Letter

Carl Icahn claims Illumina directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of Grail

Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal

Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Buy' rating for Illumina Inc (NASDAQ:ILMN) following recent activism efforts against the biotechnology company led by veteran activist investor Carl Icahn. Icahn, who owns a 1.4% stake in the San Diego-based DNA sequencing company, on March 13 issued a letter to Illumina shareholders criticizing its $7.1 billion merger with Grail and nominated three individuals to join the company's Board of Directors.

Illumina shares attractive as conclusion to Grail saga draws closer, broker says

Illumina pushed back against Carl Icahn's proxy fight over the Grail deal, saying it's committed to maximizing shareholder value as it works with regulators.

Biotech company Illumina pushes back against Carl Icahn's proxy fight over $7.1 billion Grail deal

Illumina's plan will maximize shareholder value Illumina is engaged with regulators to define GRAIL's path forward as expeditiously as possible Icahn's director nominees do not add value to the Board and will damage Illumina's core business SAN DIEGO , March 20, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued the following response to Carl Icahn's public statements and letters to Illumina's shareholders dated March 13 and March 15, 2023: Illumina's innovation engine delivers shareholder value to the core business Illumina has a successful long-term track record of innovating to fundamentally advance the understanding of biology and improve human health. Illumina is the only profitable, pure-play genomics tools company in existence.

News for Illumina Stock (ILMN)